Endoglin(EDG)是肿瘤新生血管内皮细胞膜表面蛋白,是肿瘤血管生成的标志性分子之一。树突状细胞(DC)是体内抗原提呈功能最强的抗原提呈细胞。本研究拟在完成省自然科学基金子课题"抗肺癌DC疫苗研究"和国家自然科学基金项目的子课题"EndoglinDNA疫苗诱导抗癌免疫反应"的基础上,以体内癌细胞和肿瘤新生血管内皮细胞为直接目标,依据肿瘤抗原提呈给T细胞的机理,将转染鼠EDG表达基因的原代培养的肺癌患者癌细胞与患者的DC融合成杂交细胞,该细胞与患者的T细胞混合培养诱生特异性CTL,完成体外细胞毒实验。用原代培养的人肺癌细胞与重建肺癌病人免疫系统的SCID鼠建立肿瘤动物模型,将转染鼠EDG基因的荷瘤鼠癌细胞和荷瘤鼠DC融合成杂交细胞后,再与荷瘤鼠T细胞混合培养,诱生扩增的CTL回输至荷人肺癌SCID鼠体内,研究其对体内癌细胞和肿瘤血管内皮细胞直接产生"双重"细胞毒作用所诱导的抗癌效应。
{{i.achievement_title}}
数据更新时间:2023-05-31
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation
An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function
Relationship between pulmonary function and indoor air pollution from coal combustion among adult residents in an inner-city area of southwest China
Loss of a Centrosomal Protein,Centlein, Promotes Cell Cycle Progression
Expression of MTERF3 gene in breast carcinoma and the relationship with clinicopathological characteristics
GP73+AFP+HCC/DC杂交细胞诱生特异性抗人肝癌CTL疫苗的研究
人肺癌DC疫苗诱导特异性抗肿瘤免疫效应机制的研究
重组HSV-1靶向激活DC诱导CTL抗肺癌免疫应答的实验研究
Endoglin 适配体/IP-10生物反应器定向募集特异性CTL抗肿瘤研究